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CD44v6 protein expression was not altered in activated cells. Expression 
profiles of other adhesion moecules are under investigation. Thus natural 
ligands of CD44 ie hyaluronate, have a marked effect on expression of other 
families of adhesion molecules whereas activation by specific antibody, 
while causing upregulation of MMP￿s, does not have as profound an effect on 
the adhesion molecules investigated to date.   
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ERK5 EXPRESSION IN HUMAN PROSTATE CANCER
B.L.Jenkins*, P.B.Mehta, C.N.Robson, D.E.Neal and H.Y.Leung. 
Department of Surgery, Medical School, University of Newcastle-Upon-
Tyne, NE2 4HH 
Introduction 
ERK5 is required for EGF-induced cellular proliferation and progression 
through the cell cycle
1. We have recently shown that MEK5, the specific 
activator of ERK5, is over-expressed in prostate cancer and is associated with 
metastatic disease and poor survival.  ERK5 has three splice variants, namely 
a, b, and c, encoding for different amino termini
2. The full length ERK5a is 
catalytically active, whereas the b and c forms are dominant negative kinases. 
We studied the expression of ERK5 isoforms, to further characterise the 
function of the MEK5/ERK5 pathway in human prostate cancer. 
Materials and Methods 
Primers flanking the region in which ERK5 varies in the three splice isoforms 
were designed. RNA was extracted from a panel of human prostate, bladder, 
breast and colon cancer cell lines. It was then subjected to reverse 
transcription PCR analysis. Snap frozen resected prostatic (7 BPH, 9 Cancer) 
tissue were also studied. Western blotting was performed on four of the cell 
lines to confirm ERK5 expression. 
Results 
The amplicons seen were related to the presence and size of the intron insert 
at the region of interest; a-115bp, b-175bp, c-251bp. In J82 bladder cancer 
cells, all three ERK5 isoforms were detected with the ￿a￿ and ￿c￿ forms 
predominant. In the other cell lines examined, only the ERK5 ￿a￿ variant was 
detected. Uniform ERK5￿a￿ expression was also seen in the benign and 
malignant prostate tissue throughout all the samples. Western blotting of the 
cell lines exhibited the same expression pattern as was seen in the PCR 
results. 
Discussion and conclusion 
In murine tissue all three ERK5 isoforms are expressed in testis, brain, 
kidney, lung and heart. The expression of the ￿a￿ and ￿c￿ forms are much 
stronger than the ￿b￿ form. We have shown that ERK5 ￿a￿ is expressed in 
human prostatic tissue, and the dominant negative proteins and were not 
detected. The ￿b￿ and ￿c￿ isoforms may be suppressed in active tissue 
allowing excessive growth seen in both BPH and prostate cancer. It is 
possible that manipulation of the expression of these splice variants could be 
performed to inhibit excessive growth. 
[1] Kato Y, Tapping RI, Huang S et al. 1998 Nature 395: 713 [2] Yan C, Luo 
H, Lee JD et al. 2001 J Biol Chem 276: p10870 
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Hereditary multiple exostoses (HME/EXT; MIM133700) is an autosomal 
dominant disorder characterized by the presence of multiple benign cartilage-
capped bone tumors.  It has been ascribed to mutations in two tumor 
suppressor-related genes, EXT1 and EXT2, encoding glycosyltransferases 
required for heparan sulfate proteoglycan (HSPG) synthesis.  The molecular 
basis for tumor formation is not known but a number of hypotheses have 
been proposed that center on the alteration of HSPG and deregulated 
endochondral bone formation.  These included altered Indian hedgehog (Ihh) 
signaling or fibroblast growth factor (FGF) function because diffusion of Ihh 
is thought to be regulated by HSPG, and FGF function requires binding to 
haparin.  Ihh and FGF are important molecules that regulate chondrocyte 
differentiation and proliferation in endochondral bone formation.   
To gain insight into the molecular basis for HME/EXT, we analyzed seven 
patients; two from Australia, four from Hong Kong and one from Mainland 
China for mutations in EXT1 or EXT2 genes.  A novel mutation of a single 
nucleotide deletion (386-388 delA) in exon 1, was identified in EXT1 in an 
Australian patient.  This resulted in shift of the codon reading frame from 
serine
130 with a predicted termination at position 134. In the other Australian 
patient, a previously reported mutation, G679A (D227N), in exon 2 of  EXT2
was identified.  A 1173+1 G→ T FS R360 mutation was identified in the 
Mainland patient in the EXT2 gene.  This mutation represents a nucleotide 
substitution of guanine to thymine at position 1173 at the +1 position of 
intron 7.  This mutation alters the 5￿ splice site and the most likely 
consequence is the splicing out of exon 7, resulting in a shift of the codon 
reading frame from arginine at position 360 (R360) of the amino acid 
sequence.  No mutation in either EXT1 or EXT2 was detected for the four 
patients from Hong Kong. 
Analysis of tumor samples obtained from Hong Kong and Mainland patients 
are in progress to study changes in cartilage differentiation using 
immunostaining and in situ hybridizaion.  Markers for chondrocyte 
differentiation and proliferation are being assessed together the localization 
of haparan sulfate and Ihh.  Preliminary data showed chondrocyte 
differentiation and cellular organization differs to that of a normal growth 
plate.  This study will provide insight into possible mechanisms, and a direct 
comparison of cellular changes between bone tumors with or without 
mutations in the EXT1 or EXT2 genes.  
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The association of autosomal dominant palmoplantar keratoderma (tylosis) 
and oesophageal cancer has been recognised in three families. Linkage 
analysis has mapped the TOC gene to a 250kb region on chromosome 17q25. 
The tissue-specific expression profile of four known genes within this region 
was investigated by RT-PCR, and all of these genes were shown to be active 
in the tissues of interest, namely skin, oesophagus, and squamous cell 
oesophageal cancer. 
The entire 250kb region has been examined using the online bioinformatics 
package NIX (Nucleotide Identification X) available through the UK Human 
Genome Mapping Project Resource Centre. Expression of regions of interest 
(predicted exons and ESTs) identified by NIX was investigated by RT-PCR, 
and evidence for seven novel genes within the TOC region was obtained. All 
of these genes appear to be expressed in the tissues of interest. One of these 
genes has since appeared in Genbank and has been screened for mutations in 
the TOC families, and mutation analysis is underway on a further single-exon 
gene that is registered in Genbank. 
Further characterisation of the remaining RT-PCR gene fragments, by 
IMAGE clone sequencing and cDNA library screening, will aid in the 
identification of the TOC gene by providing full-length candidate genes for 
mutation analysis. The TOC minimal region has been shown to be implicated 
in sporadic as well as familial oesophageal cancer. The prognosis for patients 
with squamous cell oesophageal cancer is generally poor, often due to late 
presentation of the tumour. Identification of the TOC gene could potentially 
have applications in novel diagnostic and therapeutic strategies for 
oesophageal cancer. 
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VARIATIONS IN THE EXPRESSION OF P53 AND DOWNSTREAM 
TARGET GENES P21 AND MDM2 IN BREAST CANCER 
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Background: In the treatment of breast cancer, clinical studies have shown 
that tumours which are clinically and histologically similar vary in their 
response to chemotherapeutic drugs. The mechanism of action of cytotoxic 
drugs is complex but in general mediated through induction of DNA damage 
and hence activation of p53 and it￿s downstream pathway. Two key gene 
products of p53, p21WAF1 and MDM2, are known to be transcriptionally 
induced by p53. p21 mediates the tumour suppressing effects of p53 and the 
MDM2 protein controls the biological activity of p53 and targets it for 
destruction.  
Aims: To examine the relationship between p53 and its key effector genes 
p21 and MDM2 in primary breast cancers treated with neo-adjuvant 
chemotherapy.  
Methods: For 26 patients with breast cancer, p53, p21 and MDM2 protein 
expression in response to chemotherapy treatment was determined by western 
blot analysis using highly sensitive human specific monoclonal antibodies. 
The results were compared with pathological data available on the patients 
following surgery and the clinical data available during a minimum three 
years follow up with full approval of the Local Ethical Committee. 
Results: Evidence of activity in the p53-MDM2 pathway was observed in 
tumours that showed a more favourable response to treatment and overall 
prognosis. No distinct relationship was seen between tumour behaviour/final 
outcome and p53-p21 axis as presence or absence of activity in this pathway 
had no clear link to the clinical/pathological variables.  
Conclusion: The data suggest the p53-MDM2 pathway is activated in breast 
cancers with more favourable prognosis. More detailed analysis may provide 
the framework for novel anti-cancer drugs that target the specific proteins 
involved. 
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COMBINATION OF MICRODISSECTION AND MICROARRAY 
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Gene expression changes may play an important role in cancer invasion. To 
evaluate this possibility, the PALM micro-laser dissection and capture system 
was employed to isolate pure populations of tumour cells from two breast 
cancer types; invasive cancer and ductal carcinoma in situ (DCIS). We 
dissected the central and peripheral areas of these tumour lesions separately 
and pooled cancer cells from 10 sections, which were obtained from 5 
different patients. By using  the TRZoL reagent, total RNA was extracted 
from microdissected tissue. The Atlas SMART
TM Probe Amplification Kit 
was used to synthesise and amplify cDNA. Probes from the periphery and 
from the centre were hybridised to duplicates of Atlas Human Cancer 1.2 
Arrays which contain 1,176 known genes. After comparing images by 
AtlasImage
TM 2.0, we have found that 22 genes changed their expression 
levels in the periphery of tumour lesions relative to the central regions of 
these tumours. 15 genes are up-regulated, and 7 genes are down-regulated ( 
arbitrary threshold of 1.5-fold or greater ). Verification that this procedure 
was identifying genes likely to be of importance in tumour invasion was 
provided by the observed up-regulation of the mesenchymal marker vimentin 
at the periphery of the tumours. Equally there was up-regulation of Rho C, 
which already has been shown to have higher expression levels in metastases 
relative to the primary tumour. TSG 101 and EF-1 α  were shown , by 
microarray analysis, to be expressed differentially between centre and 
periphery. Using immunohistochemistry, we have been able to confirm these 
findings at the protein level.  
The precision of the PALM microdissection technique allows the resolution 
of cDNA microarray gene expression analysis to be increased from the level 
of tissue analysis to analysis of one or more of its component cell 
populations. Using this method we have identified changes in gene 
expression associated with varying micro-anatomical locations within the 
developing tumour mass. 
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THE CHERNOBYL THYROID TUMOUR BANK ￿ AN INTEGRATED 
APPROACH TO RESEARCH ON CANCER 
GA Thomas,  South West Wales Cancer Institute,  Singleton Hospital, Sketty, 
Swansea SA2 8QA, on behalf of the Scientific Project Panel of the NISCTB 
The only unequivocal effect of the Chernobyl accident on human health 
shown to date is the very large rise in incidence of thyroid carcinoma in 
children, in particular papillary carcinoma.   Although the post Chernobyl 
thyroid tumours are associated with a particular aetiology, they may also 
provide general insights into the pathogenesis and molecular biology of other 
cancers.  However, up to now, one of the major problems for research has 
been access to a large number of well documented samples.   
The NISCTB (Newly Independent States Chernobyl Tumour Bank;
www.srl.cam.ac.uk/nisctb) is a unique venture.  It is the first international 
cooperation that seeks to establish and make available to the world-wide 
research community a collection of biological samples from tumours and 
normal tissues from patients for whom the aetiology of their disease is known 
￿ exposure to radioiodine in childhood.   Full ethical permission (overseen by 
the NCI of the USA) was obtained for all samples held.  In order to maximise 
information from small samples, the NISCTB supplies extracted nucleic 
acids rather than pieces of tissue for individual researchers.   Quality control 
by multiplex RT-PCR  or PCR is carried out on each tissue extract.  A full 
description of the specimen; its location within the thyroid; whether other 
tumours are present in the gland and the relative locations of material from 
which RNA and DNA is extracted after frozen section confirmation, together 
with an internationally agreed diagnosis is  recorded on the project database.  
The project has been collecting material since 1
st October 1998;  frozen 
material is available on 935 of 1161 cases and aliquots of RNA and DNA are 
currently available from 421 paired samples of tumour and normal tissue; 
DNA from whole blood and aliquots of serum is also available on over a 
third of these cases in the near future. In addition to information relating to 
the biological material, documentation and tracking of the specimens 
themselves, basic clinical information is also recorded on each patient in the 
project database.   
Material from the project is currently being used amongst other things to 
study aspects of cell cycle regulation, expression of tyrosine kinase genes 
using cDNA array and identification of ret gene rearrangement.  In the future 
this will permit results from molecular biological studies on different 
oncogenes from separate studies to be correlated to investigate possible gene 
interactions.   This project could become a paradigm for investigations on the 
mechanisms of human cancer, and provide a basis that fosters international 
collaboration in cancer research.   The investigations carried out on the 
material from the NISCTB will undoubtedly provide information not only on 
mechanisms of thyroid carcinogenesis, but also information on fundamental 
aspects of  human cancer. 
P140 
MODULATION OF THE CALPAIN-CALPASTATIN PROTEOLYTIC 
SYSTEM AND CALPAIN-MEDIATED DISASSEMBLY OF CELL-
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Tumour metastases is dependent on the disruption of both cell-cell and cell-
matrix adhesions. Intercellular and extracellular matrix adhesions are 
primarily governed by cadherin-dependent adherens junctions and integrin-
linked focal adhesion attachment sites respectively. Disruption of these 
cytoskeletal linkages is associated with enhanced cell motility and tissue 
matrix invasion. Recent studies suggest calpain-mediated proteolytic 
degradation of key components of the cadherin and focal adhesion complexes 
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subsequent loss of cell-cell and cell-matrix adhesions. The calpains represent 
a highly conserved family of non-lysosomal calcium dependent cysteine 
proteases. In vivo calpain activity is tightly regulated by its highly specific 
endogenous inhibitor, calpastatin. We have recently demonstrated that 
calpain mediated proteolytic cleavage of the focal adhesion kinase (FAK) and 
subsequent disassembly of the focal adhesion complex accompanies v-Src 
induced morphological transformation of fibroblasts contributing to increased 
cell motility (Carragher et al., 2001. J.Biol.Chem. 276:4270). Increased 
calpain activity in v-Src transformed fibroblasts also promotes cell cycle 
progression and anchorage-independent growth (Carragher et al., 2002. Mol.
Cell.Biol. 22:257). To further establish the role of calpain in tumour cell 
metastasis we have examined the role that calpain plays in regulating the 
turnover of the adhesive complexes of metastatic epithelial cells. We have 
demonstrated that the protein levels of calpain are often upregulated in 
parallel with decreased levels of calpastatin in metastatic epithelial cell lines 
relative to non-metastatic controls. Furthermore, using pharmacological 
inhibitors we have demonstrated that inhibition of calpain activity stabilizes 
integrin-linked focal adhesion complexes of both non-metastatic and 
metastatic epithelial cells. Inhibiting calpain activity also suppresses the 
disassembly of cadherin-dependent cell-cell adhesions in response to culture 
of epithelial cells in low calcium conditions. These studies indicate that 
modulation of calpain activity may contribute to the turnover of integrin-
linked focal adhesions and cadherin-dependent adherens junctions in 
metastatic epithelial cells. 
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EXCISION REPAIR CROSS-COMPLEMENTING GENE 1 (ERCC1) 
PROTEIN EXPRESSION IN COLORECTAL CANCER  
SD Richman
1*, JW Adlard
1, MT Seymour
1,P  Q uir ke
2.
1Cancer Research UK. 
2Pathology, University of Leeds. 
Introduction: The ERCC1 gene is located on chromosome 19 and encodes 
one of the major enzymes involved in nucleotide excision repair (NER)
1.
NER is the mechanism of repair of DNA adducts caused by ultraviolet 
radiation and platinum-based chemotherapies. High levels of tumour ERCC1 
mRNA expression have been linked with resistance to cisplatin in gastric 
cancer
2 and oxaliplatin in colorectal cancer
3. Determining the levels of 
mRNA expression is a complicated technique not available to most histology 
departments. We have developed a protocol for determining ERCC1 protein 
expression using immunohistochemistry (IHC) which may be a more 
practical alternative. 
Methods: Archival formalin-fixed, paraffin-embedded specimens were 
retrieved from 224 consenting patients in the MRC FOCUS clinical trial of 
chemotherapy for advanced colorectal cancer. Tissue microarrays (TMAs) 
were produced containing 0.6mm cores of tumour and where available, 
corresponding normal colonic mucosa. 0.5micron sections of TMAs were cut 
for IHC. Very small biopsies were examined as individual whole sections. A 
reproducible protocol was developed for IHC using a mouse monoclonal 
antibody to the human ERCC1 protein (Lab Vision-Neomarkers, Fremont, 
California). Staining was scored by two independent assessors as positive or 
negative, and the pattern of expression was recorded. 
Results: 224 colorectal cancers and 138 corresponding normal colonic 
mucosa specimens were assessed. 28% of normal mucosa and 33% of 
cancers were positive for ERCC1 protein expression. 76% of normal tissues 
stained with a nuclear pattern, 21% with a cytoplasmic pattern and 3% with 
both nuclear and cytoplasmic staining. For tumour tissue, the rates were 36%, 
59% and 5% respectively. Staining of whole sections, including both normal 
and malignant tissue, identified cases where normal tissue showed nuclear 
staining and adjacent tumour tissue showed cytoplasmic staining. Different 
patterns of cytoplasmic staining were observed in cancers, varying from a 
diffuse pattern to very discrete granules. 
Conclusions: Immunohistochemical staining for ERCC1 using this technique 
gives positive staining for a third of colorectal cancers. We noted a tendency 
for positive normal colonic tissue to show predominantly nuclear staining and 
for cancers to show cytoplasmic staining. ERCC1 protein is produced in the 
cytoplasm and transported to the nucleus. Some colorectal cancers may have 
dysregulation of ERCC1 protein production or transport. We are continuing 
to assess the role of ERCC1 protein expression as a predictor for response to 
oxaliplatin chemotherapy. 
References:
1McHugh PJ et al (2001). Lancet Oncol 2:483. 
2Metzger R et al (1998). J Clin Oncol 16:309. 
3Shirota Y et al (2001). J Clin Oncol 23:4298. 
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Introduction: After over 40 years of 5-Fluorouracil (5FU)-based 
chemotherapy for colorectal cancer, new agents are now available, including 
irinotecan and oxaliplatin. However, we are still unable to reliably identify 
factors that will allow selection of a chemotherapy regimen for an individual 
patient that will definitely be of benefit. Reported data on molecular 
predictive factors are so far based mainly on small numbers of patients, 
outside the setting of randomised clinical trials.
1 Even with the most studied 
marker for 5FU response, thymidylate synthase (TS), there are conflicting 
accounts of its value. The MRC CR08 (FOCUS) Trial is investigating the 
role of irinotecan and oxaliplatin and their sequencing, in addition to 5FU-
based chemotherapy for 2100 patients with advanced colorectal cancer
2 and 
is therefore an excellent opportunity to study predictive molecular variables 
in a controlled clinical setting. FOCUS is still recruiting and includes a 
request to retrieve stored pathological material for bowel cancer research. 
Methods: Over 95% of patients entering FOCUS have consented to this 
study. Archival primary tumour and when available, metastasis biopsy 
specimens are retrieved in anonymised form. Tissue microarrays (TMAs) are 
produced with multiple tumour and normal tissue cores from each patient and 
these are used for immunohistochemistry (IHC) to assess protein expression. 
Potential markers being tested by IHC include: for 5FU; TS, thymidine 
phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), for 
irinotecan; topoisomerase 1 and for oxaliplatin; excision repair cross-
complementing gene 1 (ERCC1). We are also investigating RNA expression 
of the same markers using real-time reverse transcriptase (RT-) PCR. 
Candidate DNA markers for allelic imbalance, microsatellite instability and 
gene polymorphisms are also being examined. The role of cDNA microarrays 
in identifying novel predictive factors is being investigated. 
Results: To date 300 sets of tumour blocks have been retrieved for study. 
Techniques being used and a report of the progress of the project will be 
presented at the meeting. An initial assessment of TS expression using IHC in 
229 cases, all receiving 5FU (67% alone; 33% in combination with irinotecan 
or oxaliplatin), has shown that 28% of tumours are negative (Grade 0/1) and 
72% are positive (Grade 2/3). In this preliminary group, TS staining does not 
correlate with the clinical response status after the first 3 months of 
chemotherapy (P=0.37). 
Conclusions: This study is demonstrating that large-scale retrieval and 
processing of surplus pathological material in association with randomised 
clinical trials is feasible, and gains almost universal patient consent. The large 
number of patients in FOCUS will allow chemopredictive association to be 
examined using a range of candidate markers, with greater statistical power 
than previously possible. 
References: 
1Adlard J.W. et al (2002). Lancet Oncol 3:75. 
2MRC CR08 Clinical Protocol (Version 5) June 2001. 
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IMMUNOHISTOCHEMICAL PROFILING OF PATHWAY 
ACTIVATION IN TUMORS USING ACTIVATION-SPECIFIC 
ANTIBODIES.
Katie Crosby, Michael Melnick and Bradley L. Smith, Cell Signaling 
Technology, Beverly, MA 
We have used phospho-specific antibodies to characterize the activation 
status of a broad range of therapeutically relevant signal transduction 
pathways in human breast cancer tissues by immunohistochemical 
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immunohistochemical (IHC) results with methods including Western blot 
analysis, antigen absorption and staining of embedded cells. Akt kinase 
pathway activation was demonstrated by IHC with prostate tumor-derived 
LNCaP cultured cells, which lack PTEN phosphatase.  IHC analysis of 
LNCaP cells also demonstrated the induction of apoptosis following 
inhibition of the Akt pathway. Multi-pathway IHC analysis of human breast 
tumor tissue arrays showed significant correlations among activation states of 
diverse signaling proteins and implicated multiple pathways underlying the 
neoplastic phenotype. Cluster analysis of protein activation suggests that key 
signaling pathways cluster with EGFR overexpression. In contrast, HER2 
overexpression failed to cluster with any of the pathways tested. The 
activation state of specific signaling proteins was also found to correlate with 
pathological indices and patient prognosis. This is illustrated by the 
significant correlation between the activation states of Erk/MAPK and 
estrogen receptor, and breast cancer pathological indices of tumor grade and 
lymph node status. The ability to profile the activation status of a specific 
therapeutic target, as well as those of multiple other signaling proteins will be 
an important complement to the new generation of targeted therapeutics and 
will enable effective and precise diagnosis of the molecular basis of disease. 
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Cyclin dependent protein kinases (CDKs) control cell cycle progression and 
thus provide a good target for the development of inhibitory molecules for 
cancer therapy.  To date inhibitors have been directed against the kinase 
domain of each CDK.  We aim to develop inhibitors that target the binding of 
CDK4 to cyclin D, an interaction which is essential for CDK4￿s activity.  In 
addition to inhibiting CDK4￿s ability to support cell cycle progression, our 
inhibitors are also likely to facilitate CDK4-independent activities of cyclin 
D, which are in general themselves thought to be anti-proliferative.  This two 
pronged approach should have broad applicability in the clinic.    
To screen for small molecules that would inhibit the formation of the cyclin 
D/CDK4 complex, we are using  a peptide aptamer that defines the cyclin D 
binding site.  Peptide aptamers are themselves small molecules, but ones that 
can be readily screened in a yeast two-hybrid format for those that bind to a 
protein of interest.  Because of their biological (peptidic) nature, peptide 
aptamers are particularly useful in disrupting protein-protein interactions in 
vivo.  A random peptide aptamer library consisting of peptides (20 amino 
acids long) was screened against cyclin D (see accompanying abstract).  One 
of the biologically active peptide aptamers was then used as the basis for the 
following screen. 
We are establishing a small molecule screen in a cell free system using 
bioluminescence resonance energy transfer (BRET) technology.  We intend 
to screen a small diverse compound library (10, 000 compounds) to identify 
inhibitors of the cyclin D/CDK4 complex. Results will be presented. 
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THE ADDITION OF ALL-TRANS RETINOIC ACID (ATRA) 
COUNTERACTS THE INCREASE IN BCL-2 LEVELS INDUCED BY 
CYTOTOXIC AGENTS  
K.Scatchard, K.Makrogianelli, WM. Liu, L.Goff, AZR.Rohatiner and S.Joel. 
Cancer Research UK Dept Medical Oncology, St Bartholomew￿s Hospital, 
London. 
INTRODUCTION: Over-expression of BCL-2 is common in AML and is 
associated with increased resistance to cytotoxic drugs. ATRA has been 
shown to down regulate BCL-2 levels and may thus improve 
chemosensitivity. We investigated the effects of combining ATRA with 
existing anti-leukaemic agents on BCL-2 expression and cytotoxic response 
in a panel of human leukaemic cell lines. 
METHODS: CEM, HL60, K562 and ML-1 cells were exposed for 4 days to 
IC25 concentrations of cytarabine (C), idarubicin (I) or etoposide (E) alone 
and in combination with 10 µ M ATRA (A, previously shown to be optimal 
for BCL-2 downregulation). Cell viability and % apoptosis were assessed 
daily. BCL-2 status was assessed by flow cytometry, immunoblotting and 
￿real-time￿ PCR. 
RESULTS: Exposure to low concentrations of A, I or E alone typically 
raised BCL-2 levels (in CEM cells on day 4, with 10 nM C or 3 nM I: +20 – 
9% and +22 – 4%, respectively; p<0.025). Conversely, A alone resulted in 
decreased BCL-2 by day 1, which was maintained through to day 4 (-20 – 
6% on day 1 and -14 – 8% on day 4; p<0.02). The combination of ATRA 
with cytotoxic agents typically resulted in BCL-2 levels that were lower than 
those seen with cytotoxic agents alone (at day 4 in HL60 cells: +1 – 15% 
with C alone ￿52 – 6% with C+A; p=0.038). The changes in BCL-2 protein 
correlated with changes in bcl-2 mRNA and were similar for CEM and ML-1 
cells. % viability for each cytotoxic agent – A are shown in the table. Flow 
cytometric analysis indicated cell death to be by apoptosis. 
TREATMENT  %VIABILITY DAY 4 mean –SD 
CEM HL60 K562 ML1 
Control  98 – 1  96 – 0   98 – 2   95 – 1  
A 90 – 4   75 – 4   94 – 4   82 – 6  
C 87– 6   75 – 7   75 – 4   91 – 5  
C+A 67 – 3   45 – 12   64 – 12   74 – 7  
I 41 – 4   35 – 15   60 – 10   43 – 18  
I+A 21 – 6   15 – 13   60 – 6   46 – 22  
E 43 – 4   46 – 6   66 – 1   85 – 2  
E+A  36 – 10   34 – 17   72 – 8   58 – 11  
CONCLUSIONS: These data confirm the increased cell kill reported when 
ATRA is used with cytotoxic agents, but this increased cell kill is no greater 
than additive. Whilst ATRA prevents the rise in BCL-2 seen with 
chemotherapy alone this is insufficient to cause a synergistic increase in cell 
kill. As ATRA effects the expression of many other genes, agents that target 
BCL-2 more specifically, such as Antimycin A3 may help to determine 
whether targeting BCL-2 sensitises cells to conventional agents. 
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THE DETERMINATION OF HISTONE DEACETYLASE ACTIVITY 
IN INTACT CELLS USING A NON-ISOTOPIC ASSAY 
Simon Joel
1, Catherine Mikol
1, Charles Marson
2, Jackie Perry
1, Alphonso 
Rioja
2, Simon Clark
1, Bryan Young
3. Department of Medical Oncology
1, St 
Bartholomew￿s Hospital, London, Dept of Chemistry
2, University College, 
London, Cancer Research UK
3 Molecular Oncology Lab, St Bartholomew￿s 
Hospital, London  
Inhibition of histone deacetylases (HDAC￿s) may have therapeutic potential 
in patients with malignant disease. A rapid in vitro HDAC activity assay, 
based on the deacetylation of an ￿-acetyllated lysine (MAL), has recently 
been described (Hoffmann et al, Nuc Acids Res 1999; 27: 2057-8), with 
substrate and product (ML) concentrations determined by specific HPLC 
analysis with fluorescence detection. We have further developed this assay 
for use in intact cells with a single time-point reaction. For isolated rat liver, 
enzyme, substrate (5 ￿g/mL MAL) and inhibitor at 6 conc
n were incubated at 
37￿C for 60 minutes, after which the reaction was stopped with acetonitrile, 
and MAL and the deacetylated product ML determined in the supernatant. 
For intact cells, 1x10
6 CEM cells in 1 mL medium were exposed to inhibitors 
at 6 conc
n for 60 minutes, after which MAL (20 ￿g/mL) was added for a 
further 30 minutes, all at 37￿C. Cells were then rapidly washed at 4￿C, lysed 
by sonication, the reaction stopped and MAL and ML determined in the 
supernatant. The IC50 values for % viability were determined over a 3-day 
continuous exposure in CEM cells. Results are presented in the table for  
phenylbutyrate  (NaPB),  phenylbutyrate hydroxamic acid (NaPBHA) and 
Trichostatin (TSA) 
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IC50
Rat liver  Intact CEM 
cells 
CEM cells 
NaPB  405 ￿M  9.5 mM  8.4 mM 
NaPBHA  3.1 ￿M  269 ￿M  244 ￿M 
TSA  19 nm  23 nM  119 nM 
The relative HDAC inhibitory activities of NaPB and NaPBHA are in line 
with the proposed structure of the enzyme active site. Although more time 
intensive, this modification of the HDAC activity assay for use in intact cells 
may provide a better indication of the potential biological activity of selected 
compounds.  
P147 
A CELL-BASED ELISA IS A USEFUL PHARMACODYNAMIC AND 
SCREENING TOOL TO EVALUATE CHANGES IN CELLULAR 
ACETYLATION  
Lindsay Stimson*, Yvette Newbatt, Anthea Hardcastle, Kathy Boxall, Paul 
Workman, G Wynne Aherne. Cancer Research UK Centre for Cancer 
Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, 
Surrey, SM2 5NG 
Acetylation of specific lysine residues in histone tails is an essential element 
(with phosphorylation and methylation) of an intricate histone code that 
regulates gene transcription in a temporal and context dependent manner. 
Acetylation is regulated by two classes of enzyme, histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). Several HDAC inhibitors have 
been described and some are presently in pre-clinical and clinical 
development. There is also evidence that deregulated HAT enzymes play a 
role in the progression of some cancers. No drug-like inhibitors of HATs 
have yet been described. High-throughput screening is being used in the 
Centre to screen a ~60,000 compound collection for compounds that inhibit 
HATs. Such compounds would be useful chemical probes to investigate the 
effects of HAT inhibition on cellular behaviour and could form the basis of a 
new type of chemotherapy.  It is important that a mechanism-based assay 
with relatively high throughput is available to compare compounds identified 
by screening. A cell-based ELISA (cytoblot) has been used as an alternative 
to Western blotting for determining the effects of HDAC and HAT inhibition. 
Trichostatin A (TSA), a natural product HDAC inhibitor was used as a 
positive control. Treated human colon tumour cell lines (HCT116 and HT29) 
(8000 cells/well seeded) were fixed and permeablised in 96-well plates and 
primary antibodies with different specificity for histone acetylation added. 
Following washing, a europium-labelled second antibody (PerkinElmer Life 
Sciences) was added and time-resolved fluorescence measured. Fluorescent 
counts were normalised to protein measured in the same well using BCA 
reagents. Cellular acetylation increased in response to TSA (0.01 ￿ 2.2µ M) 
compared to DMSO treated controls within as little as 15 minutes and results 
were consistent with those obtained by Western blotting. An acetylated 
protein antibody (Abcam Ltd.) has been used to determine the extent of 
cellular acetylation in cells cultured over 5 days. Acetylation peaked 24 and 
48hrs following plating out before decreasing again 72hrs - 120hrs later. The 
relationship between cellular acetylation and proliferation is being studied 
further using antibodies that recognise different histones and selective sites of 
acetylation. The ELISA is proving useful as a pharmacodynamic measure of 
HDAC inhibition in vitro and to evaluate and rank HAT inhibitors identified 
by high-throughput screening. The ELISA is also being used as a cell-based 
high throughput screen to identify compounds that either increase or decrease 
acetylation. Supported by Cancer Research UK Programme Grant 
SP2330/0203 and the Institute of Cancer Research. 
P148 
IN EXPERIMENTAL METASTASES INSULIN-LIKE GROWTH 
FACTOR BINDING PROTEIN-4 (IGFBP-4) IS EXPRESSED AT 
HIGH LEVELS 
Mc Brierty D
∗ , Harmey J, Bouchier-Hayes D 
A murine model of metastatic breast cancer has been established. 4T1.2 
murine mammary carcinoma cells are a subclone of the spontaneously arising 
BALB/c 4T1 cell line (a gift from Robin Anderson, University of 
Melbourne). Lung metastases were established by tail vein injection of 
50,000 4T1.2 cells, bone metastases by inter-tibial injection of 10,000 4T1.2 
cells. Immunohistochemistry and X-ray imaging were used to confirm that 
the tumours were bone associated. 
Tumour and normal lung and bone tissues were harvested and flash frozen in 
liquid nitrogen. RNA from the tissues was used to produce radiolabelled 
cDNA. The labelled cDNA was hybridised against a commercially available 
gene array containing 588 genes (Clontech), and the arrays were then 
exposed to X-ray film. Differential gene expression was identified using 
specialised software (Atlasimage 1.01, Clontech). Housekeeping genes were 
used on each array to normalise expression patterns between them. A number 
of genes were putatively identified as being differentially expressed between 
the bone and lung tumours. These genes were selected for further analysis. 
IGFBP-4 was found to be up-regulated in both metastases relative to normal 
tissues. These results were confirmed through Northern hybridisation and 
reverse transcription polymerase chain reaction (RT-PCR). IGFBP-4 is 
involved in the regulation of bone homeostasis. In breast cancer metastasis to 
bone there is associated bone degredation. Parathyroid hormone, normally 
released when calcium levels in the blood drop, coincides with an up-
regulation of IGFBP-4 in osteoclasts. This IGFBP-4 binds to IGFs, 
preventing the normal stimulation of osteoblats by IGFs, and therefore 
decreases osteoblast activity. 
P149 
THE TUMOUR SUPPRESSOR  PTEN AND THE CELL CYCLE 
INHIBITOR p27
KIP1 IN PROSTATE CARCINOMA AND PROSTATIC 
INTRAEPITHELIAL NEOPLASIA  (PIN) - AN 
IMMUNOHISTOCHEMICAL STUDY
Irina Fenci*, Joachim Woenckhaus,  Institut of Pathology, Justus Liebig 
University, Giessen, Germany 
Genetic abnormalities involving the PTEN locus (10q23) and loss of p27
KIP1
expression are frequently observed in prostate carcinoma, especially in 
advanced stage disease and metastases. Results of recent investigations on 
glioblastoma cell lines demonstrated that PTEN determines cell cycle arrest 
in G1 by activating p27
KIP1.  However,  it is currently  unknown if a 
functional relationship exists between PTEN and p27
KIP1 in the human 
prostate carcinoma and if this connection can lead to the initiation and/or 
progression of the disease.  
In this study PTEN and p27
KIP1expression status were 
immunohistochemically assessed on serial slides in 46 primary prostate 
carcinomas (23 prostatectomies and 23 transurethral resections), 20 prostatic 
intraepithelial neoplasias associated to the carcinomas and 15 separate 
metastases. The results were correlated with the Gleason score (< 7 = low 
Gleason score, >7 = high Gleason score). We defined a cut-off level for 
p27
KIP1 of 40% positive nuclei. 
Ten of the 20 PIN lesions (50%) showed loss of at least one marker and 
p27
KIP1 was more frequently affected than PTEN (p<0,05). Simultaneous 
PTEN and p27
KIP1 deletion was observed in only 1 case (5%). The disease 
progression from PIN to cancer (assessed by comparing the staining pattern 
in PIN and cancer lesions of the same case) associated loss of PTEN in 39% 
of cases and loss of p27
KIP1 in 15,8% of cases, but no concomitant PTEN and 
p27
KIP1 loss.
Nine of 19 carcinomas with low Gleason score (47,3%) showed loss of at 
least one marker; the same pattern was noticed in 18 of 27 high Gleason 
scores (66,7%). Seven of 27 high-Gleason scores (25,9%) associated 
concomitant deletion of both markers, whereas only 2 low-Gleason 
carcinomas showed this pattern (10,5%). Similar to PIN, the low-Gleason 
scores correlated with loss of p27
KIP1 but not with loss of PTEN (p<0,05). 
Surprisingly, 10 of the 15 metastases (66,7%) showed positive signals for 
PTEN , whereas p27
KIP1 was under 40% (mean 14,2 %) in all but one case. 
These data taken together suggest that: 1) loss of p27
KIP1 occurs earlier and is 
more frequent than PTEN protein loss in the prostate carcinoma 2) the 
progression of PIN to invasive carcinoma could be determined by separate 
loss of PTEN or p27
KIP1 proteins, but not by a negative regulation of p27
KIP1
through PTEN protein deletion, 3) the low-differentiated carcinomas and the 
metastases maintain a surprisingly high PTEN expression, associated with 
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KIP1 levels, 4) p27
KIP1 seems to be down-regulated in prostate 
carcinoma by other pathways than those involving PTEN. 
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REGULATION AND INTRACELLULAR LOCATION OF PROTEIN 
KINASE B/AKT IN HUMAN PROSTATIC CELL LINES 
R Michael Sharrard* and Norman J Maitland, YCR Cancer Research Unit, 
Dept. of Biology, University of York, York YO10 5YW 
Protein Kinase B (PKB, also known as Akt) is a key intracellular signalling 
enzyme which regulates cell survival, motility, and gene transcription via the 
apoptotic regulator protein BAD, the Forkhead transcriptional regulators, 
GSK-3, and caspase 9.  PKB is activated by phosphorylation at thr308 and 
ser473 by phosphatidylinositol-dependent kinases (PDKs).  PKB and the 
PDKs are activated at intracellular membranes by PIP3 generated by 
phosphatidylinositol 3-kinase (PI3K) in response to soluble growth factors 
(GFs) and integrin- or cadherin-mediated cell adhesion.  PKB is 
downregulated by PTEN tumour-suppressor protein, which inactivates PIP3. 
We studied PKB activation in cell lines derived from human non-tumour 
prostate epithelium (PNT2, PNT1a) and from prostate tumour metastases 
(LNCaP, PC3).  Phosphorylation of PKB was assayed using antibodies 
specific to the ser473- and thr308-phosphorylated protein forms in Western 
blot probing and immunocytochemistry. The non-tumour cells showed strong 
dependence on soluble GFs for maintenance of PKB activation.  EGF (5 
ng/ml) caused a rapid (<5 min) peak of activation followed by a gradual (>30 
min) decline, while 5 ng/ml IGF-I or IGF-II caused a slower (>30 min) 
increase to higher final levels of phosphorylation.  The tumour cells 
maintained high levels of PKB activation in the absence of exogenous GFs.  
Inhibition of PI3K by 10
-5M LY294002 resulted in rapid loss of PKB 
activation (<30 min) in the non-tumour cells, followed by partial recovery 
over 2-3 hours.  In contrast, the tumour cells showed a slower (3 hours) 
response to LY294002 which did not reverse.  PKB activation in the different 
cell lines was paralleled by levels of phosphorylation of GSK-3 and by levels 
of S and G2/M phases and maintenance of cell growth.  Confocal microscopy 
showed that phosphorylated PKB was located at the plasma membrane in the 
tumour cells, while in the non-tumour cells it was largely associated with 
particulate or vesicular cytoplasmic structures, where it was resistant to 
LY294002.  Cells transfected with myc-tagged PDK-1 or with the pleckstrin 
homology domain of PKB fused to green fluorescent protein revealed a 
similar pattern, indicating that PKB activation and location is PIP3-
dependent. 
PKB activation in normal prostatic epithelial cells thus appears to be 
maintained by GF-dependent, LY294002-resistant generation of cytoplasmic 
vesicle-associated PIP3 by PI3K, while in tumour cells the PIP3 is largely 
generated at the plasma membrane by PI3K which is independent of 
exogenous GFs, but extremely sensitive to LY294002. These studies suggest 
that drugs which inhibit PI3K and its products may be selectively therapeutic 
in treatment of advanced prostate cancer.      Supported by YCR and MRC. 
P151 
HUMAN SPROUTY2 (A NOVEL INHIBITOR OF FGF RECEPTOR 
SIGNALLING) IN HUMAN PROSTATE CANCER
Douglas DA*, Mehta PB, Neal DE, Leung HY 
Prostate Research Group, Department of Surgical Sciences, Medical School, 
University of Newcastle upon Tyne. NE2 4HH 
INTRODUCTION:  
The Fibroblast Growth Factors (FGFs) and their receptors (FGFRs) are 
important in prostate cancer pathogenesis. Over-expression of multiple 
members of the FGF family (FGF1, FGF2, FGF7 and FGF8), occur in 
prostate cancer. FGFs activate FGF Receptors. FGFR1 and FGFR2 are over-
expressed in prostate cancer. 
Sprouty protein was first described in Drosophila to regulate airway 
development. It functions in a competitive fashion to block FGF mediated 
signalling. It has similar activities in vertebrates. The expression of Sprouty is 
induced by activation of FGFR and therefore serves as a physiologic negative 
feedback to control the function of activated receptors. Over-expression of 
Sprouty blocks FGF mediated signalling enough to result in an altered 
phenotype. We aimed to examine expression levels of hSprouty2 in human 
prostate cancer. 
MATERIALS AND METHODS:  
RNA was extracted from 62 BPH and malignant prostate chips. Expression 
of hSprouty2 was examined within prostate samples using Reverse 
Transcription (RT)-PCR and Western Blot analysis. Sprouty mRNA 
expression was quantitated by Real Time RT-PCR, which is currently the 
most sensitive method for mRNA quantitation.  
RESULTS:
Expression of hSprouty2 was compared between benign prostate hypertrophy 
(BPH), low grade (Gleason 2-4), moderate grade (Gleason 5-7) and high 
grade (Gleason 8-10) prostate carcinoma. Levels in BPH and low grade 
carcinoma were similar, and although moderate grade carcinoma showed a 
downward trend in Sprouty expression, this was not significant. When 
compared to the BPH group, hSprouty2 mRNA expression was significantly 
reduced in high grade tumours (p<0.005).  
CONCLUSIONS:  
Expression of hSprouty2 (a physiologic inhibitor of FGFR) is significantly 
down-regulated in high grade prostate cancer.  The functional significance of 
such hSprouty2 down-regulation warrants further investigation. 
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METHYLATION OF GSTP-1, CD44, E-CADHERIN AND RASSF1A 
IN NORMAL AND MALIGNANT PROSTATE TISSUE
K Patel*
1, K MacLennan
1, PJ Selby
1, S Burchill
1
1Division of Cancer Medicine Research Cancer Research UK Clinical Centre, 
St. James￿s University Hospital, Leeds, U.K. e-mail: 
medkp@cancermed.leeds.ac.uk 
Sensitive methods for the detection of prostate cancer may be useful in 
defining prognosis and in directing future therapeutic strategies.  RT-PCR for 
PSA mRNA in the peripheral blood of cancer patients has been studied by 
our group and others and found it to be sensitive but lacking in absolute 
specificity. Identification of tumour specific molecular abnormalities should 
circumvent this problem, however consistent tumour specific abnormalities 
have not been identified in prostate cancer. Abnormal methylation of 5￿ CpG 
islands within promoter regions of tumour suppressor genes have been 
identified in prostate cancer (GSTP1, CD44 and e-cadherin) and proposed as 
a mechanism of inactivation of these genes. These tumour specific 
abnormalities within GSTP1, CD44 and e-cadherin were studied further in 
prostate tumours as well as RASSF1A a putative tumour suppressor gene in 
bladder and nasopharyngeal cancers. DNA from eleven laser-microdissected 
prostate tumour needle biopsies and 5 non-malignant prostate biopsies were 
modified with bisulphite and methylation examined using a sensitive nested 
methylation -specific PCR.   
GSTP1 methylation was detected in all tumours, CD44 methylation in 5/11 
tumours, e-cadherin methylation in 1/11 tumours and RASSF1A methylation 
in 10/11 tumours. 
Non-malignant prostate biopsies from men with elevated serum PSA levels 
also showed methylation patterns for all 4 genes. 
The methylation status of GSTP1 and CD44 concurs with other studies in 
prostate cancer, however e-cadherin methylation was rarely seen. RASSF1A 
was also methylated in prostate cancer (novel observation). 
Interestingly, methylation of these genes was also found in age-matched non-
malignant prostate tissue. We hypothesise that the methylation patterns seen 
in normal tissues may be an age-related change or be part of a spectrum of 
￿background￿ changes seen prior to the malignant phenotype. Tumour 
specificity for methylation of the 4 genes studied was not demonstrated. 
Poster Presentations
S80
British Journal of Cancer (2002) 86(Suppl 1), S34–S121 ã 2002 Cancer Research UKP153 
INVESTIGATION OF THE INVASIVE CAPACITY OF BASAL CELL 
CARCINOMA USING AN INVASION ASSAY MODEL 
P. Lim*
1, GD Wilson
2, R Sanders
1
1RAFT Institute of Plastic Surgery & Gray Cancer Institute 
2Mount Vernon Hospital, Northwood, Middlesex 
Basal cell carcinoma (BCC) is the commonest cancer in humans and presents 
major problems in terms of surgery for the patient and workload for the NHS 
with over 40000 cases of BCC each year in the UK. 
Despite this there has been relatively little research into BCC compared to 
other skin cancers. We have previously shown that in aggressive BCC there 
is an increased expression of matrix mealloproteinase-2 (MMP-2) and 
reduced expression of its inhibitor TIMP-2.  MMPs have been implicated in 
the invasion and metastasis process in a number of different tumours.  We are 
examining if the invasive properties of BCC and investigating if these can be 
modified with inhibitors of MMPs. 
Invasion studies were performed using the cell line of BCC, KMC-1/BCC 
and primary cell lines isolated from surgical specimens. Suspensions of the 
BCC cells were placed in the upper compartment of the invasion chamber 
and these were attracted to conditioned media in the lower chamber. Invasive 
cells that migrated through matrigel-coated filters were stained and counted. 
It has been possible to use this experimental model to examine the effect of a 
number of substances on BCCs including TIMP-2 and synthetic MMP 
inhibitors such as ilomastat. Provisional results suggest that the invasive 
capacity of BCC can be reduced by MMP inhibitors. 
P154 
CHANGES IN THE APOPTOTIC PHENOTYPE OF PROSTATIC 
EPITHELIAL CELLS DURING THEIR DIFFERENTIATION FROM 
BASAL TO LUMINAL SECRETORY 
Declan G Murphy*, John M Fitzpatrick, R. William G. Watson 
Department of Surgery, Mater Misericordiae Hospital, Conway Institute of 
Biomolecular and Biomedical Research, University College Dublin, Ireland. 
Basal prostate epithelial cells differentiate into an endstage luminal cell 
which is dependent on the presence of androgen. Why these cells become 
androgen dependent and susceptible to cell death via apoptosis remains 
unknown. We hypothesise that alterations in the apoptotic phenotype of the 
luminal prostate epithelial cells ultimately leads to its dependence on 
androgen and susceptibility to apoptosis. 
The NRP-152 cell line is a benign basal cell line derived from the dorsal-
lateral prostate of the rat. Under mitogen-deficient conditions, NRP-152 cells 
were differentiated from a basal to a luminal prostate epithelial cell. Using 
Western Blotting immunofluorescence, this change in phenotype was 
confirmed by the progessive loss of cytokeratin 14 expression and the 
increased expression of cytokeratin 18, over an 8 day time-course. The 
expression of the apoptotic proteins Bcl-2, MCL-1, cIAP-1, cIAP-2 and 
caspase 3 were then characterised. Western blotting demonstrated that the 
anti-apoptotic proteins Bcl-2, MCL-1, cIAP-1 and cIAP-2 all decreased in 
expression in a time dependent manner. However, the expression of the pro-
apoptotic protein, caspase-3, was unchanged.  
These findings suggest that prostatic luminal cells become more susceptible 
to apoptosis during differentiation as a result of decreased expression of anti-
apoptotic proteins. Further characterisation of these apoptotic changes will 
help define the potential areas in the differentiation process where 
carcinogenesis and hormone-independence may occur.  
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CELL CYCLE CHECKPOINT RESPONSE AND MICRONUCLEUS 
FORMATION INDUCED BY UVA RADIATION IN CELLS FROM 
INDIVIDUALS HARBOURING GERMLINE MUTATIONS IN BRCA1 
S.E. Tobi
1*, J. Shorrocks
1, R. Eeles
2, J.H.Peacock
2 and T.J.McMillan
1
1Dept. of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, 
2
Institute of Cancer Research, Sutton, Surrey, SM2 5NG 
Individuals carrying germline mutant alleles of the BRCA1 gene have an 
increased risk of developing breast and ovarian cancer. A number of 
observations point to the participation of the  BRCA1 protein in the cellular 
response to DNA damage and, more specifically, there is evidence for its 
involvement in regulating cell cycle checkpoints after ionising radiation. 
Using primary human diploid fibroblasts from individuals either wild-type 
for BRCA1 or containing a mutant allele (heterozygous), we examined the 
cell cycle response following exposure of exponentially￿growing cells to the 
oxidative stress induced by UVA radiation (320-400nm). Although cells from 
all individuals exhibited a G1 arrest after UVA (100kJ/m
2 ), the response was 
of a shorter duration in the BRCA1 (+/-) heterozygotes. Thus, 14 hours after 
irradiation, the proportion of cells in S-phase in three wild-type fibroblast 
strains (expressed as percentages (mean ±  range) of corresponding   
unirradiated values) was 20.33 ±  5.36, 16.85 ±  2.25 and 7.85 ±  2.41, as 
compared to values of 33.78 ±  1.52 and 37.53 ±  1.52 for two BRCA1 (+/-) 
strains. Since a defective G1/S checkpoint in BRCA1 heterozygotes could 
lead to a greater proportion of S-phase cells with unrepaired DNA damage 
(strand breaks) and a resultant increase in chromosomal instability, the 
frequency of micronuclei induced by UVA was examined. Three normal 
(+/+) and three mutant (+/-) strains (two of which were used in the cell cycle 
experiments) produced mean micronuclei frequencies of  0.080 ±  0.013 and 
0.094 ±  0.031/binucleate cell respectively (not statistically significant), 48h 
after UVA exposure . Our data suggest a defective G1/S checkpoint in cells 
from  BRCA1 heterozygotes in response to UVA radiation although this is 
not reflected in genomic instability as measured by micronuclei induction. 
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INTRACELLULAR SIGNALING IN THE NFκκκκ B ACTIVATION 
PATHWAY FOLLOWING OXIDATIVE STRESS MEASURED BY 
FLUORESCENCE LIFETIME IMAGING OF FLUORESCENT 
PROTEINS 
Sarah A. Roberts*
1, Simon M. Ameer-Beg
2, Borivoj Vojnovic
2 and Peter 
Wardman
1, Free Radicals in Cancer
1 and Advanced Technology
2 Groups, 
Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, 
Middlesex, HA6 2JR, UK 
Fluorescence resonance energy transfer (FRET) between spectrally different 
chromophores has allowed the study of protein-protein interactions to be 
followed within the cell. In this study, spatially resolved FRET was measured 
by multiphoton fluorescence lifetime imaging microscopy, which provides a 
method for following changes in the lifetimes of fluorescently tagged 
proteins, indicating a change in protein environment inside both live and 
fixed cells.  
NFκ B is a transcription factor that is activated by a wide variety of stimuli 
including ionizing radiation and many anticancer agents. Its activation has 
been shown to be cytoprotective and may reduce the efficacy of many 
anticancer drugs. Oxidative stress has also been shown to activate NFκ B, but 
only in certain cell lines. However, in all cell lines examined NFκ B
activation was inhibited by the addition of antioxidants. In order to determine 
whether reactive oxygen species are involved in NFκ B activation and where 
in the NFκ B pathway they exert their effect, we have used green fluorescent 
protein (GFP) tagged fusion proteins of NFκ B and other members of the 
signalling pathway to examine lifetime changes following a variety of stimuli 
inducing oxidative stress. Measurements were performed by analysis of 
fluorescence decay kinetics acquired using single photon counting following 
two-photon excitation (ca 150 fs 890 nm pulses), on a pixel-by-pixel basis.  
We initially examined the interaction between Iκ Bα  (inhibitory subunit of 
NFκ B) and its activating kinase IKK in MCF-7 cells transiently transfected 
with both GFP fused Iκ Bα  and FLAG-tagged IKK. Following treatment, the 
cells were fixed and the IKK protein was labelled with AlexFluor 532. By 
stimulating of the cells with activators of NFκ B, a reduction in the average 
lifetime of GFP was observed indicating the proteins change in the 
environment. This reduction was only observed in the cytoplasm of the cell 
(not in the nucleus) confirming the cytoplasmic localization of the Iκ Bα /IKK 
interactions. When lifetime data were fitted with biphasic kinetics 
quantitative measurements of FRET efficiency were obtained which allowed 
measurements of the distance between the two proteins during interaction. 
Oxidative stress (100 µ M H2O2) was able to stimulate members of the NFκ B
activation pathway in this MCF-7 cell line as measured by FRET and 
confirmed by Western Blot analysis of NFκ B and Iκ Bα  proteins. In 
conclusion, the results show that analysis of the lifetime images was 
successful in reporting interactions between the proteins Iκ Bα  and IKK. 
This work is supported by the Cancer Research UK.
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THE EFFECT OF CONJUGATED LINOLEIC ACID (CLA) AND ITS 
ISOMERS ON THE PROLIFERATION, MIGRATION AND 
INVASION OF A METASTATIC MURINE MAMMARY CELL LINE   
`ine O￿Connor*, Susan McDonnell
1, Rosaleen Devery
1, Catherine Stanton
2.
School of Biotechnology, 
1National Institute for Cellular Biotechnology, 
Dublin City University, Dublin 9, Ireland and 
2Teagasc Dairy Products 
Research Centre, Moorepark, Fermoy, Co. Cork, Ireland. 
Conjugated Linoleic Acid (CLA), a polyunsaturated fatty acid, refers to a 
group of dienoic derivatives of linoleic acid that can be found in natural food 
sources, such as milk fat and the meat of ruminant animals.  CLA has been 
shown to have anti-carcinogenic activity in many in vitro and in vivo studies.  
Previous studies have focused on the effects of dietary CLA on the 
prevention of tumour appearance, yet relatively little is known about the 
actual mechanism of CLA￿s anti-cancer activity. 
The most lethal aspect of cancer is the ability of tumour cells to metastasise 
and form secondary tumours.  The matrix metalloproteinases (MMPs), a 
multi-gene family of enzymes, degrade components of the extracellular 
matrix (ECM).  The MMPs have been implicated as major role players in 
tumour invasion and metastasis.  The aim of this study was to examine the 
effect of CLA on the growth, MMP-9 expression and invasive activity of a 
murine mammary tumour cell line, 4T1, which is known to be highly 
metastatic  in vivo.
Cells were treated with CLA, which contains a mixture of various isomers, 
and with the purified predominant isomers present in CLA, 9c,11t(18:2) and 
10t,12c(18:2).  Cytotoxicity was examined using a Promega Proliferation 
assay, with varying CLA concentrations and time points chosen.  Sub-lethal 
as well as lethal doses were determined.  Interestingly, it appeared that the 
10t,12c(18:2) isomer had the most lethal effect, killing the cells with an IC50
of 13µ g/mL when incubated for 2 days. In contrast, the CLA mix and the 
9c,11t(18:2) isomer had an IC50 of 40 and 20 µ g/mL, respectively, when 
incubated for 4 days. 
Treatment of the cells with a sub-lethal dose of CLA and its isomers also 
resulted in a reduction in the invasive activity of the cell line.  This was 
assayed by coating Matrigel (Sigma), which acts as ECM, onto 8µ m pore-
size membranes through which cells invade in vitro.  Whilst, the CLA mix 
reduced invasion compared to control (ethanol) treated cells, the isomers 
again appeared more potent than the CLA mix.  Using substrate zymography, 
which measures MMP activity, the amount of MMP-9 expressed by the 4T1 
cells was also reduced by treatment with CLA and its isomers.   
Both the invasion assays and the MMP analyses indicate strongly that CLA 
may be used as an anti-metastatic agent in vitro.  In vivo work using this fatty 
acid and this cell line, for the induction of lung nodules, will be the next step 
in elucidating the importance of CLA in anti-cancer treatments.  
P158 
THE ROLE OF CD44 AND EZRIN DURING PROSTATE CANCER-
ENDOTHELIUM INTERACTION.   
Gregory M. Harrison*1, W. G. Jiang1, M D Mason2. 1Departments of 
Surgery and 2Clinical Oncology, University of Wales College of Medicine 
Cardiff. UK. 
CD44 is a multifunctional cell surface adhesion molecule that has been 
implicated in tumour cell invasion and metastasis. Many cancer cell types as 
well as their metastases expresses high levels of CD44. It is known that ezrin, 
a member of the ERM family of proteins, can bind to CD44 and thus raises 
the possibility that it is involved in cell migration and metastasis. Therefore 
we examined the expression and distribution of CD44, its co-localisation and 
translocation with ezrin in prostate cancer cell lines as they interact with 
endothelial cells.  
RT-PCR revealed multiple isoforms of CD44 were expressed in DU-145 and 
PC-3 and DNA Sequencing identified both the standard and different variant 
isoforms in both cells. CD44 and ezrin were found to associate with each 
other in prostate cancer cell lines as seen by immunoprecipitation and 
Western blotting. In addition, incubation of cells with Hepatocyte growth 
factor/scatter factor (HGF/SF), a cytokine know to enhance cancer invasion 
and migration, resulted in the up regulation of CD44 expression in both PC-3 
and DU-145 cells as seen by Western blotting.  Dual-immunofluorescence 
and laser scanning confocal microscopy revealed the co-localisation of CD44 
and ezrin but also the co-translocation of these proteins in response to 
HGF/SF exposure. Using a tumour-endothelial adhesion assay, more 
HGF/SF-activated PC-3 cells were found adhered to endothelial cells than 
untreated PC-3 cells and adhesion was further increased by pre-activated 
endothelium with HGF/SF. Results from an in vitro invasion assay confirm a 
significant increase in the invasive potential of HGF-treated cells. The 
increased adhesion and invasiveness were reduced or abolished by the 
inclusion of anti-CD44 antibodies or the addition of an excess hyaluronic 
acid (HA). 
In conclusion, the change in distribution of CD44-Ezrin complex and up-
regulation of CD44 suggest CD44 plays a role in the initial capture and 
subsequent invasion of endothelium by prostate tumour cells.  
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A CELL MODEL SYSTEM TO STUDY THE MOLECULAR BASIS 
OF EXT MUTATIONS USING IN VITRO CHONDROGENESIS 
Helen C.M. Leung*, Danny Chan, Kathryn S.E. Cheah, and Daisy K.Y. 
Shum  
Department of Biochemistry, The University of Hong Kong, Hong Kong, 
China
Mutations in Ext1 and Ext2 are associated with Hereditary Multiple 
Exostoses (HME), which is characterized by benign cartilage-capped 
outgrowths (exostoses) from ends of long bones. The Ext1 and Ext2 proteins 
possess a copolymerase activity that participates in heparan sulphate (HS) 
chain extension on the linker tetrasaccharide to the core protein of 
proteoglycans (PGs). Cell surface PGs can interact with diffusible growth 
factors (FGFs) and signaling molecules (Ihh) expressed in the growth plate 
cartilage and thus play a part in regulating bone development. A hypothesis is 
that mutations in the Ext1 and Ext2 genes alters HS synthesis, in terms of the 
length of HS chains and sulphation pattern, leading to defective 
chondrogenesis as a prelude to the formation of exostoses. 
Previous studies on Ext1 and Ext2 mutations have demonstrated a number of 
mutations act in a dominant-negative manner leading to defective HS chain 
synthesis.  However, these studies were carried out in non-chondrogenic cell 
line. Our objective is to establish tools and a cell based model system 
required to study the molecular and cellular changes during chondrogenesis.  
In this system, we will exploit the ability of a mouse chondrogenic progenitor 
cell line, ATDC5 that undergoes in vitro chondrogenesis in culture.  We have 
initiated stable transfections with expression plasmids for wild type ext1 and 
ext2 cDNA, and cDNA plasmids with dominant-negative mutations in ext1
(R340C) and ext2 (D227N) genes.  This will allow the opportunity to monitor 
the effect of the mutations on proteoglycan synthesis.  In particular, extension 
of haparan sulphate chain and sulphation pattern. More importantly, we can 
monitor and compare the progression of in vitro chondrogenesis and to 
address the responsiveness of transfected cells to Indian Hedgehog (Ihh) 
signaling. Experiments are also in progress to establish efficient protocol to 
monitor haparan sulphate synthesis using a newly developed fluorescent-
assisted carbohydrate electrophoresis. 
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INTERACTIONS BETWEEN CD44, BETA-1 INTEGRIN AND THE 
MATRIX METALLOPROTEINASES IN REGULATING 
COLORECTAL CANCER CELL ADHESION AND INVASION 
D. Murray*, S. McDonnell 
School of Biotechnology, National Institute for Cellular Biotechnology, 
Dublin City University, Dublin 9, Republic of Ireland. 
The complex process of tumour cell invasion involves the attachment of cells 
to the extracellular matrix (ECM), degradation of the ECM and subsequent 
migration and detachment of cells from the ECM.  Cell adhesion molecules 
like CD44 and integrins are key players in such cell-cell, as well as cell-
matrix, adhesion interactions.  Beta￿1 integrin mediated signal transduction is 
thought to up-regulate matrix metalloproteinase (MMP) expression via the 
mitogen activated protein kinase (MAPK) pathway.  Collectively, members 
of the MMP family can degrade the ECM completely.  Such extracellular 
proteolytic activities have given the MMPs well established roles in tumour 
cell migration and invasion.  Appreciating the importance of both attachment 
Poster Presentations
S82
British Journal of Cancer (2002) 86(Suppl 1), S34–S121 ã 2002 Cancer Research UKto and degradation of the ECM in tumour cell invasion, it is no longer 
appropriate to consider CD44, integrins and MMPs as acting in isolation. 
This research aims to elucidate the interactions of these molecules in 
regulating colorectal tumour metastasis.  
The expression of CD44 and beta-1 integrin was examined in the primary 
human colon carcinoma cell line SW480, its lymph node metastatic 
derivative SW620 and SW480(Mut-6) which have been transfected with the 
gene for Matrilysin (MMP-7).  The SW480(Mut-6) has been shown to be 
more invasive than the parental SW480.  Western blot analysis showed that 
the SW480, SW620 and SW480(Mut-6) expressed an 80kDa variant of CD44 
with increased expression in the SW620.  The expression of a 120kDa variant 
of CD44 was also observed in SW620 but not in SW480 or SW480(Mut-6).  
The SW620 cell line also expressed higher levels of Beta-1 integrin than the 
other cell lines.  The adhesion of these cell lines on plastic, fibronectin and 
hyaluronic acid was also examined.  Results showed that there was a 
significant difference in cell attachment between these cell lines.  The SW620 
and SW480(Mut-6) were more adherent to plastic than the parental SW480.  
The SW480(Mut-6) were also shown to be more adherent to fibronectin and 
hyaluronic acid than SW480. In contrast, the SW620 appeared to be less 
adherent to hyaluronic acid than SW480.  These results demonstrate that 
MMP-7, CD44 and beta-1 integrin interact with each other to regulate 
colorectal tumour cell attachment and migration.  This work will help 
elucidate the functional relationships of these molecules in controlling 
invasion and metastasis in colorectal cancer.  
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THE BISPHOSPHONATE ZOLEDRONIC ACID UPREGULATES 
APOPTOTIC SIGNALS AND IMPAIRS THE ADHESION OF 
BREAST CANCER CELLS TO MINERALISED MATRICES PRIOR 
TO THE INDUCTION OF APOPTOSIS 
Lisa M Pickering*, Siddhika G Senaratne, Janine L Mansi, Kay W Colston 
St. George￿s Hospital Medical School, Cranmer Terrace, London. UK. SW17 
0RE. 
AIMS. Bisphosphonates are of proven efficacy in limiting skeletal related 
morbidity in patients with advanced breast cancer. The mechanisms by which 
these compounds exert their clinically important effects remain inadequately 
understood. We have previously demonstrated that bisphosphonates directly 
induce apoptosis in the breast cancer cell lines MCF-7 and MDA-MB-231
1.
We aimed to further elucidate the signalling pathways of these effects. We 
also aimed to investigate the relationship between bisphosphonate induced 
breast cancer cell apoptosis and effects on adhesion to bone-like dentine 
matrices.  
PROCEDURES.  Breast cancer cells were incubated in medium 
supplemented with zoledronic acid or vehicle. Apoptosis was assessed 
morphologically and by colourimetric assays of cell proliferation and cell 
viability. Immunoblotting was performed using a standard assay comprising 
gel electrophoresis, transfer to a nitro-cellulose membrane, protein detection 
with primary and secondary antibodies and protein visualisation against 
colour standards by chemiluminescence. Adhesion assays were performed by 
seeding treated breast cancer cells onto mineralised matrix for 1 ￿ 24 hours. 
Adherent cells were fixed, stained and counted.  
MAJOR FINDINGS. Zoledronic acid induced apoptosis in the breast cancer 
cell lines MDA-MB-231, MCF-7, SKBR3 and HS578T. Treatment of MDA-
MB-231 and MCF-7 breast cancer cells with 100 µ M zoledronic acid resulted 
in downregulation of the anti-apoptotic protein bcl-2 and upregulation of the 
pro-apoptotic protein bax. The importance of bcl-2 as a survival signal was 
confirmed by the demonstration that forced bcl-2 expression in MDA-MB-
231 cells abrogated the effects of zoledronic acid. Pro-caspase 3 cleavage 
was demonstrated by a FACS based assay in MDA-MB-231 cells but not in 
MCF-7 cells which constitutively lack caspase 3. However, MCF-7 cells 
underwent a time-related cleavage of caspase 7 in response to treatment with 
zoledronic acid. Finally we provide evidence to suggest that zoledronic acid 
can impair the normally observed adhesion of breast cancer cells to 
mineralised matrix in a dose and time dependent manner and moreover that 
this occurs at an earlier time point than that required to observe its apoptotic 
effects.  
SIGNIFICANCE OF RESEARCH. Our findings suggest that clinical 
responses to bisphosphonates in patients with breast skeletal metastasis are 
related to induction of apoptosis. This may occur through impaired cell-
matrix interactions resulting in anoikis.  
CONCLUSIONS. We suggest that zoledronic acid-induced impairment of 
breast cancer cell adhesion occurs prior to induction of apoptosis and anoikis 
may play a role in bisphosphonate induced cell death. The precise effector 
signals of this pathway remain to be determined. 
1. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. 2000. Br J 
Cancer;82:1459 
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HES6 REGULATES MYOGENIC DIFFERENTIATION 
Cossins, J
1, Vernon, A E
2 , Zhang, Y
1, Philpott A
2 and Jones P H
2 *,  
1 Cancer Research UK, Weatherall Institute of Molecular Medicine, John 
Radcliffe Hospital, Oxford, UK.  2 Cancer Research UK Department of 
Oncology, University of Cambridge, Hutchison/MRC Research Centre, 
Addenbrooke￿s Hospital, Cambridge, UK 
In rhabdomyosarcoma, tumour cells fail to undergo the cell cycle withdrawal 
and terminal differentiation that occur in normal muscle differentiation.   
Candidate regulators of proliferation and differentiation in normal and 
malignant myogenesis are the Hes proteins, basic helix-loop-helix 
transcription factors homologous to Enhancer of Split (EoS) proteins that 
regulate differentiation in Drosophila.   
We identified Hes6 as a member of the Hes family expressed in normal 
muscle and rhabdomyosarcoma by database searches.  Hes6 is known to 
promote neural differentiation and to bind to Hes1, a related protein that has 
been implicated in cell cycle regulation, affecting Hes1 function.  Here, we 
show that Hes6 is expressed in the murine embryonic myotome and is 
induced on C2C12 myoblast differentiation in vitro.  Hes6 binds DNA 
containing the Enhancer of Split E box (ESE) motif, the preferred binding 
site of Drosophila EoS proteins, and represses transcription of an ESE box 
reporter.  When overexpressed in C2C12 cells, Hes6 impairs normal 
differentiation, causing a decrease in the induction of the cyclin dependent 
kinase inhibitor, p21
Cip1, and an increase in the number of cells that can be 
recruited back into the cell cycle after differentiation in culture.  
Hes6 is well conserved in Xenopus, so we used this system to study the effect 
of Hes6 on myogenesis in vivo.  In situ hybridisation in embryonic Xenopus 
reveals that Hes6 is co-expressed with the early muscle marker, MyoD.   
Microinjection of Hes6 RNA in Xenopus embryos results in an expansion of 
the myotome, but suppression of terminal muscle differentiation and 
disruption of somite formation at the tailbud stage, paralleling the phenotype 
seen in vitro.  Analysis of Hes6 mutants indicates that whilst the DNA 
binding activity of Hes6 is not essential for its myogenic phenotype, protein-
protein interactions mediated by the C terminus of the protein are required.   
Thus we demonstrate a novel role for Hes6 in multiple stages of muscle 
formation, and that down regulation of Hes6 expression is required for 
terminal differentiation of muscle.  We plan to investigate if Hes6 is highly 
expressed in rhabdomyosarcoma and identify Hes6 interacting proteins.
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METHIONINE DEPENDENCY OF TUMOURS: A BIOCHEMICAL 
STRATEGY FOR SYNCHRONISING CELLS IN SPECIFIC PHASES 
OF THE CELL CYCLE. 
V Pavillard*, DJ Swaine, RM Phillips, A Nicolaou, & JA Double 
Cancer Research Unit and School of Pharmacy, University of Bradford, 
Bradford BD7 1DP, UK. 
A well established feature of tumour cell proliferation (Hoffman BBA 1984, 
738: 49-87) is their dependence upon the essential amino acid methionine 
(MET) whereas normal cells are MET independent. Tumour cells cultured in 
medium which is deprived of MET but supplemented with its precursor, 
homocysteine (HCY) show a marked decrease in cell proliferation in 
conjunction with a distinct accumulation of cells in the S/G2 phase. Release 
of the cell cycle blockade by addition of MET (following a period of MET 
starvation) has not been previously studied. It offers the potential of 
synchronising cells in a specific phase of the cell cycle thereby rendering 
cells more susceptible to cell cycle phase specific agents and producing 
therapeutic gain. The cell lines used in this study were rat hepatocarcinoma 
lines HTC (MET dependent), Phi-1 (partially MET independent) and the 
human skin fibroblast cell line, Hs-27 (MET independent). Under standard 
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